Ewing Sarcoma (ES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Ewing Sarcoma (ES) Market Outlook
Thelansis’s “Ewing Sarcoma (ES) Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Ewing Sarcoma (ES) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Ewing
Sarcoma (ES) Overview
Ewing
sarcoma (ES), a peripheral primitive neuroectodermal tumor, is a malignancy
originating from a specific cell type in either bone or soft tissue. This tumor
condition is characterized by chromosomal rearrangements involving the long
arms (q) of chromosomes 11 and 22 (11q24-22q12), resulting in the abnormal
fusion of two genes, typically EWS and FLI. The standard approach to treating
ES, whether it has metastasized or not, involves a multidisciplinary approach
that includes chemotherapy and local therapies such as surgery and radiotherapy
(RT). Complications associated with Ewing sarcoma may include metastasis, local
recurrence, secondary cancers, pathological fractures, and morbidities
associated with surgery, radiation, and chemotherapy. Ewing sarcoma primarily
affects adolescents and young adults, with a median age of onset at 15 years.
It accounts for less than 5% of all soft tissue sarcomas. The highest incidence
occurs between the ages of 10 and 15, with approximately 30% of cases diagnosed
in children under 10 and another 30% in adults over 20. There is a notable male
predominance, with a male-to-female ratio of 3 to 1.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment